



## Complete Summary

---

### **GUIDELINE TITLE**

Guidelines for the diagnosis and treatment of pediculosis capitis (head lice) in children and adults 2008.

### **BIBLIOGRAPHIC SOURCE(S)**

University of Texas, School of Nursing, Family Nurse Practitioner Program. Guidelines for the diagnosis and treatment of pediculosis capitis (head lice) in children and adults. Austin (TX): University of Texas, School of Nursing; 2008 May. 17 p. [19 references]

### **GUIDELINE STATUS**

This is the current release of this guideline.

This guideline updates a previous version: University of Texas at Austin, School of Nursing, Family Nurse Practitioner Program. Recommendations for the treatment of pediculosis capitis (head lice) in children. Austin (TX): University of Texas at Austin, School of Nursing; 2002 May. 13 p. [41 references]

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
CONTRAINDICATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### **DISEASE/CONDITION(S)**

Pediculosis capitis (head lice)

### **GUIDELINE CATEGORY**

Diagnosis  
Evaluation  
Management  
Prevention  
Treatment

## **CLINICAL SPECIALTY**

Dermatology  
Family Practice  
Infectious Diseases  
Internal Medicine  
Nursing  
Pediatrics

## **INTENDED USERS**

Advanced Practice Nurses  
Health Care Providers  
Managed Care Organizations  
Nurses  
Physician Assistants  
Physicians  
Public Health Departments

## **GUIDELINE OBJECTIVE(S)**

To present a national guideline on the management of pediculosis capitis

## **TARGET POPULATION**

Children and adults in the United States with pediculosis capitis

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Diagnosis/Evaluation**

1. Detection of head lice by direct visualization of head and scalp
2. Detection using fine-tooth louse comb

### **Management/Treatment**

1. Pediculicidal regimens
  - Permethrin 1%
  - Pyrethrin 0.33% and piperonyl butoxide 4%
  - Malathion 0.5% lotion
  - Ivermectin oral 200 micrograms/kg
  - Permethrin 1% and/or trimethoprim and sulfamethoxazole
  - Lindane 1% shampoo
2. Alternative regimen for removal of head lice
  - Combing wet hair with conditioner and fine-tooth comb

3. Other management considerations
  - Treatment of family members
  - Treatment of personal hair care items
  - Laundering of bedding
  - Notification of schools or child care facilities
  - Resistance to pediculicides
  - Hair washing considerations before, during, and after treatment with a pediculocide

## **MAJOR OUTCOMES CONSIDERED**

- Alleviation of signs and symptoms
- Prevention of sequelae of infestation
- Prevention of transmission
- Toxicity of drug treatment

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

To select evidence for critical appraisal by the group the Medline (U.S. National Library of Medicine) EBSCO database was searched for the years 2004-2008 using the keywords "head lice" and "pediculosis capitis" in the title, abstract, and indexing forms. Additional resources were found using bibliographies of relevant articles.

### **NUMBER OF SOURCE DOCUMENTS**

19

### **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Expert Consensus  
Weighting According to a Rating Scheme (Scheme Given)

### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

**Quality of Evidence** (Based on the U.S. Preventive Services Task Force Ratings)

**Good:** Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.

**Fair:** Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence of health outcomes.

**Poor:** Evidence is insufficient to assess the effects on health outcomes because of limited number of power of studies, important flaws in their designs or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

## **METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review

## **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Review of the literature with group consensus. Consideration was given to patient preferences and length of treatment.

## **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

## **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Guidelines were drafted by graduate students following review of the literature.

## **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

**Grading of Recommendations** (Based on the U.S. Preventive Services Task Force Ratings)

**A.** There is good evidence that the recommendation improves important health outcomes. Benefits substantially outweigh harms.

**B.** There is at least fair evidence that the recommendation improves important health outcomes. Benefits outweigh harms.

**C.** There is at least fair evidence that the service can improve health outcomes but the balance of benefits and harms is too close to justify a general recommendation.

**D.** There is at least fair evidence that the recommendation is ineffective or that harms outweigh benefits.

**I.** Evidence that the service is effective is lacking, of poor quality or conflicting and the balance of benefits and harms cannot be determined.

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

The Family Nurse Practitioner students submitted the draft recommendations to the University of Texas at Austin School of Nursing faculty for review. The draft was later revised to incorporate faculty recommendations.

## **RECOMMENDATIONS**

### **MAJOR RECOMMENDATIONS**

Strength of recommendations (A, B, C, D, I) and quality of evidence (good, fair, poor) are defined at the end of "Major Recommendations" field.

#### **Diagnosis**

- Finding a live louse or nymph on the scalp or a viable egg within 1cm of the scalp (Elston, 2005; Mumcuoglu et al., 2006; Roberts & Burgess, 2005)
  - Nits that are within 6 mm from the scalp are usually viable and are highly suggestive of an active infestation (Ko & Elston, 2004; Leung, Fong, & Pinto-Rojas, 2005).
  - Nits that are more than 1cm from the scalp are generally not viable (Leung, Fong, & Pinto-Rojas, 2005).
  - Using a light source, a magnifying lens and parting the hair at the scalp may aid in detection (Sciscione & Krause-Parello, 2007).
- Lice eggs or nits may be easier to detect, especially behind the ears or at the nape of the neck
- Using a fine-tooth louse comb is 4 times more efficient than direct visual examination and twice as fast (Elston, 2005; Mumcuoglu et al, 2006).

#### **Evidence Good, Recommendation A**

#### **Recommended Regimens**

- 1% Permethrin is treatment of choice because of efficacy and lack of toxicity (Burkhart, 2004; Burkhart & Burkhart, 2006; Downs, 2004; Elston, 2005; Hansen, 2004; Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Leung, Fong, & Pinto-Rojas, 2005).
  - 1% Permethrin cream rinse is applied to the hair and scalp for 10 minutes and then rinsed off.
  - A second treatment is advised 7 to 10 days later to ensure cure.

#### **Evidence Good, Recommendation B**

- Pyrethrin 0.33% and piperonyl butoxide 4% (Burkhart, 2004; Burkhart & Burkhart, 2006; Elston, 2005; Hansen, 2004; Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Leung, Fong, & Pinto-Rojas, 2005).
  - Product is applied to hair that is first shampooed and then towel dried, left on for 10 minutes, and then rinsed off.
  - These agents are not ovicidal and application should be repeated 7 days later to ensure cure.

#### **Evidence Good, Recommendation B**

- 0.5% Malathion lotion (Burkhart, 2004; Burkhart & Burkhart, 2006; Downs, 2004; Elston, 2005; Hansen, 2004; Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Leung, Fong, & Pinto-Rojas, 2005; Meinking et al., 2007; West, 2004).
  - The lotion is applied to the hair until thoroughly moistened, left to air dry, and then rinsed off after 8 to 12 hours.
    - A drawback to its use is its lengthy application time (Meinking et al., 2007).
    - Some authors report success with 0.5% malathion gel formulation, which only requires a 30-minute application time (Meinking et al., 2007).
  - The application should be repeated in 7 to 9 days if live lice are still present at that time.
  - Safety and efficacy have not been established in children less than 6 years of age.
  - Preferred first line treatment in regions where pyrethroid resistance has been observed.

#### **Evidence Good, Recommendation B**

#### **Alternative Regimens**

- Combing of wet hair using a conditioner of choice and a fine-tooth louse comb (Downs, 2004; Elston, 2005; Ibarra et al., 2007; Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Mumcuoglu et al., 2007; Tebruegge & Runnacles, 2007).
  - Wet combing is treatment of choice for children younger than 2 years of age (Leung, Fong, & Pinto-Rojas, 2005).
  - Repeat combing needs to be done over 2 weeks on days 1, 5, 9, and 13 to break the life-cycle (Ibarra et al., 2007).
  - Because no pediculicide is 100% ovicidal, removal of nits by wet combing is recommended by some authors (Leung, Fong, & Pinto-Rojas, 2005).

#### **Evidence Good, Recommendation C**

- Ivermectin 200 micrograms/kilogram orally (PO) with a repeat dose 2 weeks later (Burkhart, 2004; Burkhart & Burkhart, 2006; Elston, 2005; Dourmishev, Dourmishev, & Schwartz, 2005; Downs, 2004; Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; West, 2004).

- Topical ivermectin holds some promise for the treatment of head lice, but oral ivermectin is the only form licensed for human use in the United States.

### **Evidence Fair, Recommendation C**

- A combination of 1% permethrin and/or trimethoprim 10 mg/kg/day and sulfamethoxazole 50 mg/kg/day in 2 divided doses for 10 days (Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Leung, Fong, & Pinto-Rojas, 2005).
  - Should only be reserved for cases not responsive to traditional pediculicides or suspected cases of lice-related resistance to therapy.

### **Evidence Fair, Recommendation C**

- Lindane shampoo 1% (60 mL) (Burkhart, 2004; Downs, 2004; Elston, 2005; Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Leung, Fong, & Pinto-Rojas, 2005; West, 2004).
  - Should be used only in patients who cannot tolerate first-line treatment, or in whom first-line treatment with safer products has failed (Burkhart, 2004; Hansen, 2004).
  - Wash hair with regular shampoo at least 1 hour before applying lindane and dry thoroughly. Do not use any creams, oils, or conditioners.
  - Shake the shampoo well. Apply just enough shampoo to make hair and scalp wet.
  - Throw away any remaining shampoo.
  - Leave the lindane shampoo on hair for exactly 4 minutes. Longer exposure times may cause seizures or other serious problems. Keep hair uncovered during this time.
  - At the end of 4 minutes, use a small amount of warm water to lather the shampoo. Do not use hot water.
  - Wash all of the shampoo off of hair and skin with warm water.
  - Dry hair with a clean towel.
  - Comb hair with a fine tooth comb (nit comb) or use tweezers to remove nits (lice eggs and larvae).
  - Should not be reapplied if initial treatment fails (Burkhart, 2004).

### **Evidence Good, Recommendation D**

### **Other Management Considerations**

- Family members should be treated only if infected (Elewski, 2005; Lebwohl, Clark, & Levitt, 2007; Leung, Fong, & Pinto-Rojas, 2005).
- Personal hair care items should be treated with pediculocides or soaked in hot water (Ko & Elston, 2004; Leung, Fong, & Pinto-Rojas, 2005).
- Bedding should be laundered in hot water of at least 50 degrees Celsius and tumble dried on the hot cycle for 40 minutes, or dry cleaned within 48 hours of contact of head of an infested person (Izri & Chosidow, 2006; Ko & Elston, 2004).
- Schools or child care facilities should be notified so that additional cases can be detected and treated (Ko & Elston, 2004; Lebwohl, Clark, & Levitt, 2007; Mumcuoglu et al., 2007; Sciscione, 2007).

- Resistance to pediculocides has been detected in some areas of the country. Consider resistance in your area when determining treatment (Hansen, 2004; Mumcuoglu et al., 2007).
- Towel dry hair before using treatment as too much water in the hair dilutes the pediculicide, decreasing its efficacy.
- Do not use a cream rinse or conditioner shampoo before using the treatment as it will interfere with the medication.
- Do not wash hair for 1 to 2 days after treatment.
- Long hair may require more than 1 bottle of product per treatment. In most cases, 50 mL of product is required for each application. In those patients with long or thick hair, up to 150 mL may be required.

### **Evidence Fair, Recommendation C**

#### **Follow-Up**

- If infestation persists after 2 treatments consider evaluating for correct use of product and an alternative agent should be used (Hansen, 2004).
  - Causes of treatment failure in head lice infestations include misdiagnosis, noncompliance or not following product instructions, reinfestation, or resistance of lice to the pediculicide.

### **Evidence Good, Recommendation B**

#### **Special Considerations**

- Children younger than 2 years of age
  - Wet combing is the only treatment recommended for children younger than 2 years (Leung, Fong, & Pinto-Rojas, 2005).

### **Evidence Good, Recommendation A**

- Pregnancy
  - Permethrin, pyrethrin, and malathion are category 'B' drugs.

### **Evidence Good, Recommendation A**

#### **Definitions:**

**Quality of Evidence** (Based on U.S. Preventive Services Task Force [USPSTF] Ratings)

**Good:** Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.

**Fair:** Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence of health outcomes.



**Poor:** Evidence is insufficient to assess the effects on health outcomes because of limited number of power of studies, important flaws in their designs or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

#### **Grading of Recommendations** (Based on USPSTF Ratings)

**A.** There is good evidence that the recommendation improves important health outcomes. Benefits substantially outweigh harms.

**B.** There is at least fair evidence that the recommendation improves important health outcomes. Benefits outweigh harms.

**C.** There is at least fair evidence that the service can improve health outcomes but the balance of benefits and harms is too close to justify a general recommendation.

**D.** There is at least fair evidence that the recommendation is ineffective or that harms outweigh benefits.

**I.** Evidence that the service is effective is lacking, of poor quality or conflicting and the balance of benefits and harms cannot be determined.

#### **CLINICAL ALGORITHM(S)**

A clinical algorithm on detection, treatment, and management of head lice is provided in the original guideline document.

### **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

#### **REFERENCES SUPPORTING THE RECOMMENDATIONS**

[References open in a new window](#)

#### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations" field).

### **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

#### **POTENTIAL BENEFITS**

- Appropriate diagnosis and treatment of pediculosis capitis
- Decreased transmission of pediculosis capitis
- Decreased re-infection rate
- Decreased risk of secondary infections

#### **POTENTIAL HARMS**

- Pediculicides may cause burning, stinging, itching, or irritation at the site of application.
- Conjunctivitis has been reported with the use of malathion following contact with the eyes.
- Malathion is flammable and should therefore be kept away from open flames and electric heat sources such as hair dryers and curling irons.
- Possible significant adverse reactions can occur with the use of ivermectin and trimethoprim/sulfamethoxazole, so consider patient risk factors and consult a drug reference before prescribing.
- Exposure to lindane shampoo for longer than 4 minutes may cause seizures or other serious problems.

### **Pregnancy Considerations**

Permethrin, pyrethrin, and malathion are category 'B' drugs.

## **CONTRAINDICATIONS**

### **CONTRAINDICATIONS**

- Contraindications for permethrin include hypersensitivity to pyrethroid, pyrethrin, chrysanthemums, or any component of the formulation. The lotion is also contraindicated for use in infants less than two months of age.
- Contraindications for the use of pyrethrin include hypersensitivity to pyrethrins, ragweed, chrysanthemums, or any component of the formulation.
- Contraindications for the use of malathion include hypersensitivity to malathion or any component of the formulation, and use in neonates or infants.
- Contraindications to Ivermectin therapy are allergic sensitization, nervous system disorders, pregnancy, and lactation. Ivermectin therapy should not be recommended for children younger than 5 years or less than 15 kg in weight.
- Contraindications for trimethoprim/sulfamethoxazole include hypersensitivity to any sulfa drug, trimethoprim, or any component of the formulation, porphyria, megaloblastic anemia due to folate deficiency, infants less than two months of age, marked hepatic damage, severe renal disease, and pregnancy (at term).

## **QUALIFYING STATEMENTS**

### **QUALIFYING STATEMENTS**

- The vast majority of trials reviewed included only children as the majority of infestations occur between the ages of three and 11.
- These recommendations are meant to serve as a source of clinical guidance. Health care providers should always consider the individual clinical circumstances of each person in the context of local disease prevalence as well as resistance. These guidelines focus on the treatment and counseling of individual patients and do not address other components of a community that are important in pediculosis capitis detection and prevention, such as schools and daycare centers.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

### IMPLEMENTATION TOOLS

Clinical Algorithm

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better  
Staying Healthy

### IOM DOMAIN

Effectiveness  
Patient-centeredness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

University of Texas, School of Nursing, Family Nurse Practitioner Program. Guidelines for the diagnosis and treatment of pediculosis capitis (head lice) in children and adults. Austin (TX): University of Texas, School of Nursing; 2008 May. 17 p. [19 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2002 May (revised 2008 May)

### GUIDELINE DEVELOPER(S)

University of Texas at Austin School of Nursing, Family Nurse Practitioner Program  
- Academic Institution

### SOURCE(S) OF FUNDING

Not stated

## **GUIDELINE COMMITTEE**

Practice Guidelines Committee

## **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

*Authors:* Vishwa Bhatt, RN, FNP; Ellen Curnutte, RN, FNP; James Moore, RN, MSN, FNP

*Consultant:* Frances Sonstein, MSN, FNP, CNS

## **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

## **GUIDELINE STATUS**

This is the current release of this guideline.

This guideline updates a previous version: University of Texas at Austin, School of Nursing, Family Nurse Practitioner Program. Recommendations for the treatment of pediculosis capitis (head lice) in children. Austin (TX): University of Texas at Austin, School of Nursing; 2002 May. 13 p. [41 references]

## **GUIDELINE AVAILABILITY**

Electronic copies: None available.

Print copies: Available from the University of Texas at Austin, School of Nursing, 1700 Red River, Austin, Texas, 78701-1499

## **AVAILABILITY OF COMPANION DOCUMENTS**

None available

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This NGC summary was completed by ECRI on October 3, 2002. The information was verified by the guideline developer on October 16, 2002. This summary was updated by ECRI Institute on September 18, 2008.

## **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which may be subject to the guideline developer's copyright restrictions.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/24/2008

